Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation

• Published in: Frontiers in aging neuroscience 2020-06, Vol.12, p.152-152
• Main Authors: Belloli, Sara, Morari, Michele, Murtaj, Valentina, Valtorta, Silvia, Moresco, Rosa Maria, Gilardi, Maria Carla
• Format: Article
• Language: English
• Subjects: Animal models; Basal ganglia; Brain; Chemokines; Computed tomography; Cytokines; Diacetyl; Dopamine; Dopamine receptors; early disease markers; Etiology; Fibrillogenesis; Glutamatergic transmission; Immune system; Inflammation; Macrophages; Magnetic resonance imaging; Microbiota; Microglia; Morphology; Movement disorders; Neostriatum; Neurodegeneration; Neurodegenerative diseases; Neuroimaging; neuroinflammation; Neurons; Neuroscience; Nonsteroidal anti-inflammatory drugs; Oxidative stress; Parkinson's disease; Pathogenesis; Pathology; PD models; PET radioligands; Phenotypes; Positron emission tomography; Single photon emission computed tomography; Tumor necrosis factor-TNF
• ISSN: 1663-4365; 1663-4365
• DOI: 10.3389/fnagi.2020.00152

Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and appearance of α-synuclein insoluble aggregates known as Lewy bodies. Neurodegeneration is accompanied by neuroinflammation mediated by cytokines and chemokines produced by the activated microglia. Several studies demonstrated that such inflammatory process is an early event, and contributes to oxidative stress and mitochondrial dysfunctions. α-synuclein fibrillization and aggregation activate microglia and contribute to disease onset and progression. Mutations in different genes, exacerbate the inflammatory phenotype in the monogenic compared to sporadic forms of PD. Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) with selected radiopharmaceuticals allow in vivo imaging of molecular modifications in the brain of living subjects. Several publications showed a reduction of dopaminergic terminals and dopamine (DA) content in the basal ganglia, starting from early stages of the disease. Moreover, non-dopaminergic neuronal pathways are also affected, as shown by in vivo studies with serotonergic and glutamatergic radiotracers. The role played by the immune system during illness progression could be investigated with PET ligands that target the microglia/macrophage Translocator protein (TSPO) receptor. These agents have been used in PD patients and rodent models, although often without attempting correlations with other molecular or functional parameters. For example, neurodegeneration and brain plasticity can be monitored using the metabolic marker 2-Deoxy-2-[18F]fluoroglucose ([18F]-FDG), while oxidative stress can be probed using the copper-labelled diacetyl-bis(N-methylthiosemicarbazone) ([Cu]-ATSM) radioligand, whose striatal-specific binding ratio in PD patients seems to correlate with disease rating scale and motor scores. In addition, structural and functional modifications during disease progression may be evaluated by Magnetic Resonance Imaging (MRI), using different parameters as iron content or cerebral volume. In this review, we propose an overview of in vivo clinical and non-clinical imaging research on neuroinflammation as an emerging marker of early PD. We also discuss how multimodal-imaging approaches could provide more insights into the role of inflammatory process and related events in PD development.